Used in cancer immunotherapy, particularly for targeting B7-H3 (CD276), a protein overexpressed in various solid tumors including neuroblastoma, glioblastoma, and sarcomas. The antibody is engineered for high specificity to deliver targeted radiation or therapeutic agents directly to tumor cells while sparing healthy tissue. It has been investigated in intracerebrospinal fluid or intratumoral delivery to treat central nervous system cancers and metastases. In clinical settings, it enables imaging and therapeutic monitoring by binding to tumor sites, allowing for precise detection and localized treatment. Its application supports minimal off-target effects and improved tumor control in early-phase trials.